Connect your AI

CYPH CYPH Research And Development Incentive Receivable Current

Research And Development Incentive Receivable Current at other companies

Replimune GroupREPL

$2.96M-3.6%

VAN

Vivani MedicalVANI

$685K+291%

Replimune GroupREPL

-$1.63M-473%

AltimmuneALT

$518K-79.9%

Replimune GroupREPL

$341K-9.3%

VAN

Vivani MedicalVANI

$43K+155%

Other financials

Income statement

Revenue$375.0K—

Operating income-$4.8M+69.7%

Net income-$77.2M-400%

EPS (diluted)-$0.46-24.3%

Balance sheet

Cash & equivalents$6.7M-79.6%

Total debt$38.0K-75.3%

Total equity$84.4M+305%

Total assets$87.4M+151%

Cash flow

Operating cash flow-$3.4M+76.3%

Valuation

Market cap$65.19M-54.5%

Enterprise value$58.54M—

P/S43.5×—

Profitability

Operating margin-2,761.7%—

Net margin-2,705.8%—

Returns & leverage

Return on equity-108.2%-34.4pp

Debt / equity0×0.0×

Current ratio27.3×+24.9×

Where this comes from

Reported directly by CYPH in its filing.

Tagged under the XBRL concept cyph:ResearchAndDevelopmentIncentiveReceivableCurrent.

The official record: CYPH’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CYPH's research and development incentive receivable current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CYPH's research and development incentive receivable current?: CYPH (CYPH) reported research and development incentive receivable current of $616K in Q1 2026.
What does research and development incentive receivable current mean?: This metric tracks the amount of government grants, tax credits, or research subsidies that the company expects to receive within one year for qualifying innovation activities. It serves as a key indicator of the company's ability to offset high R&D costs through external funding mechanisms. A higher balance suggests effective utilization of government innovation programs to support product development.